http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2780274-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3747bf64d40e3a84d36f688cd74b5bc |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2019-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_095dc63de9a2a21d36a4e90644a2bcd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ccc5f93060db7e0522f6b62f2c406d0 |
| publicationDate | 2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2780274-A1 |
| titleOfInvention | Cortistatin or an analog thereof as a pharmaceutically active agent in latent form |
| abstract | Cortistatin or an analog thereof as a pharmaceutically active agent in latent form. The half-life in blood of endogenous peptides such as somatostatin and cortistatin is extremely short, reaching only a few minutes (Skamene et al., Clin Endocrinol 1984, 20, 555-564). Therefore, there is a need to find new systems or compositions comprising cortistatin or an analog thereof for the treatment of those pathologies in which specific cortistatin receptors are expressed and those receptors shared with other molecules such as somatostatin (sstr1, sstr2 , sstr3, sstr4 and / or sstr5) and / or ghrelin (GHSR), being also more stable in blood than cortistatin. The present invention provides improved means of providing cortistatin or an analog thereof as a pharmaceutically active agent in latent form, more stable in blood than cortistatin, which releases cortistatin in a controlled release mode. |
| priorityDate | 2019-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 498.